Trastuzumab deruxtecan (DS-8201a), a HER2-targeting antibody–drug conjugate, demonstrates in vitro and in vivo antitumor activity against primary and metastatic ovarian tumors overexpressing HER2 - Levent Mutlu; Blair McNamara; Stefania Bellone; Diego D. Manavella; Cem Demirkiran; Michelle Greenman; Miguel Skyler Z. Verzosa; Natalia Buza; Pei Hui; Tobias Max Philipp Hartwich; Justin Harold; Yang Yang-Hartwich; et al. (Clinical & Experimental Metastasis, 2024)

Class III β-tubulin overexpression within the tumor microenvironment is a prognostic biomarker for poor overall survival in ovarian cancer patients treated with neoadjuvant carboplatin/paclitaxel - Dana M. Roque; Natalia Buza; Michelle Glasgow; Stefania Bellone; Ileana Bortolomai; Sara Gasparrini; Emiliano Cocco; Elena Ratner; Dan-Arin Silasi; Masoud Azodi; Thomas J. Rutherford; Peter E. Schwartz; et al. (Clinical & Experimental Metastasis, 2014)

Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor - Emiliano Cocco; Joyce Varughese; Natalia Buza; Stefania Bellone; Ken-Yu Lin; Marta Bellone; Paola Todeschini; Dan-Arin Silasi; Masoud Azodi; Peter E. Schwartz; Thomas J. Rutherford; Luisa Carrara; et al. (Clinical & Experimental Metastasis, 2011)